TWI776827B - 能夠調節配體結合活性的配體結合分子 - Google Patents

能夠調節配體結合活性的配體結合分子 Download PDF

Info

Publication number
TWI776827B
TWI776827B TW106141341A TW106141341A TWI776827B TW I776827 B TWI776827 B TW I776827B TW 106141341 A TW106141341 A TW 106141341A TW 106141341 A TW106141341 A TW 106141341A TW I776827 B TWI776827 B TW I776827B
Authority
TW
Taiwan
Prior art keywords
ligand
antibody
protease
seq
binding molecule
Prior art date
Application number
TW106141341A
Other languages
English (en)
Chinese (zh)
Other versions
TW201833136A (zh
Inventor
井川智之
石川広幸
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW201833136A publication Critical patent/TW201833136A/zh
Application granted granted Critical
Publication of TWI776827B publication Critical patent/TWI776827B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
TW106141341A 2016-11-28 2017-11-28 能夠調節配體結合活性的配體結合分子 TWI776827B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016229882 2016-11-28
JP2016-229882 2016-11-28

Publications (2)

Publication Number Publication Date
TW201833136A TW201833136A (zh) 2018-09-16
TWI776827B true TWI776827B (zh) 2022-09-11

Family

ID=62195875

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111105054A TW202235438A (zh) 2016-11-28 2017-11-28 能夠調節配體結合活性的配體結合分子
TW106141341A TWI776827B (zh) 2016-11-28 2017-11-28 能夠調節配體結合活性的配體結合分子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW111105054A TW202235438A (zh) 2016-11-28 2017-11-28 能夠調節配體結合活性的配體結合分子

Country Status (12)

Country Link
US (2) US12060654B2 (enExample)
EP (1) EP3546480A4 (enExample)
JP (3) JP7626577B2 (enExample)
KR (2) KR20230073346A (enExample)
CN (1) CN110214151A (enExample)
AU (1) AU2017364818C1 (enExample)
BR (1) BR112019008265A2 (enExample)
CA (1) CA3039316A1 (enExample)
IL (1) IL266827B2 (enExample)
MX (3) MX2019005947A (enExample)
TW (2) TW202235438A (enExample)
WO (1) WO2018097308A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
MX2019005947A (es) 2016-11-28 2019-08-26 Chugai Pharmaceutical Co Ltd Molecula de union a ligando que tiene actividad de union a ligando ajustable.
KR20200089312A (ko) * 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR20250134208A (ko) * 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
IL278615B1 (en) * 2018-05-14 2025-10-01 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of using them
US20210253672A1 (en) * 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
WO2019230867A1 (en) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN113164558A (zh) * 2018-09-28 2021-07-23 皮埃尔法布雷医药公司 用于治疗癌症的新型免疫细胞因子
MX2021004496A (es) * 2018-10-22 2021-06-04 Univ Pittsburgh Commonwealth Sys Higher Education Activadores segmentables de cxcr3 y metodos de uso.
EP3892330A4 (en) * 2018-12-04 2022-10-26 Chugai Seiyaku Kabushiki Kaisha CXCR3 LIGAND
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
JP7716979B2 (ja) * 2019-06-05 2025-08-01 中外製薬株式会社 プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
US20220281934A1 (en) * 2019-08-29 2022-09-08 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
JP2023510994A (ja) * 2020-01-20 2023-03-16 中外製薬株式会社 リガンド結合融合タンパク質
EP3889183A1 (en) * 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
TW202321281A (zh) * 2021-07-19 2023-06-01 日商中外製藥股份有限公司 使用融合多肽之蛋白酶媒介之靶特異性細胞激素傳遞
US20250073307A1 (en) 2021-12-23 2025-03-06 Chugai Seiyaku Kabushiki Kaisha Cxcr3 ligand having enhanced cxcr3-expressing cell migration activity
CN120112547A (zh) 2022-11-16 2025-06-06 瑞泽恩制药公司 包含膜结合il-12和蛋白酶可裂解接头的嵌合蛋白

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK2208784T3 (da) 2001-06-22 2013-03-18 Chugai Pharmaceutical Co Ltd Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CN1665932B (zh) 2002-04-30 2010-12-15 株式会社载体研究所 具有修饰的蛋白酶依赖向性的载体
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
EP1675878A2 (en) 2003-10-24 2006-07-05 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
JP2005168328A (ja) 2003-12-08 2005-06-30 Hokkaido Univ シグナル伝達活性を有する細胞質蛋白質の活性制御方法
KR101333449B1 (ko) 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ｉｐ―１０ 항체 및 그의 용도
DK1735439T3 (da) 2004-04-12 2012-02-06 Catalyst Biosciences Inc Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
CN102702353A (zh) 2004-07-09 2012-10-03 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
CA2591813A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007063311A2 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
KR20140072201A (ko) 2006-07-05 2014-06-12 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
CA2659574C (en) 2006-08-02 2017-04-25 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
AU2008219570B2 (en) 2007-02-28 2013-08-22 Novimmune Sa Human anti-IP-10 antibodies and uses thereof
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
AU2008265984B2 (en) 2007-06-21 2014-07-17 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
AU2016213702C1 (en) 2007-08-22 2018-11-29 Cytomx Therapeutics, Inc. Activatable binding polypeptides and methods of identification and use thereof
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
KR101470690B1 (ko) 2009-04-10 2014-12-10 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
JP2011026294A (ja) 2009-06-26 2011-02-10 Canon Inc 化合物
KR20120053042A (ko) 2009-08-17 2012-05-24 로슈 글리카트 아게 표적화된 면역접합체
WO2011123683A2 (en) 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
US9193791B2 (en) 2010-08-03 2015-11-24 City Of Hope Development of masked therapeutic antibodies to limit off-target effects
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
KR20150030639A (ko) 2012-03-30 2015-03-20 바이엘 헬스케어 엘엘씨 프로테아제로 조절된 항체
NZ781091A (en) 2012-04-06 2022-04-29 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
JP6178846B2 (ja) 2012-05-22 2017-08-09 ライフ テクノロジーズ エーエス 組み換え抗体組成物およびその使用方法
KR20150037857A (ko) 2012-06-22 2015-04-08 싸이톰스 테라퓨틱스, 인크. 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
US9850316B2 (en) 2013-02-15 2017-12-26 National University Corporation Kyoto Institute Of Technology Method for refolding antibody, process for producing refolded antibody, refolded antibody, and uses thereof
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
IL302642B2 (en) 2014-01-31 2025-04-01 Cytomx Therapeutics Inc Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof
CA2935665A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
AU2015292406B2 (en) 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
GB201413357D0 (en) 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
MX2017003847A (es) 2014-09-25 2017-12-15 Amgen Inc Proteinas biespecificas activables por proteasas.
US20180125988A1 (en) 2014-11-11 2018-05-10 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
HK1250997A1 (zh) 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
ES2796698T3 (es) 2015-05-04 2020-11-30 Cytomx Therapeutics Inc Anticuerpos anti-CD166 activables y procedimientos de uso de los mismos
CN107922490A (zh) 2015-05-04 2018-04-17 西托姆克斯治疗公司 抗ITGa3抗体、可活化抗ITGa3抗体及其使用方法
US10179817B2 (en) 2015-05-04 2019-01-15 Cytomx Therapeutics, Inc. Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
JP6841754B2 (ja) 2015-05-13 2021-03-10 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
EP3433280B1 (en) 2016-03-22 2023-04-19 F. Hoffmann-La Roche AG Protease-activated t cell bispecific molecules
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
AU2017355446A1 (en) 2016-11-03 2019-05-02 Bristol-Myers Squibb Company Activatable anti-CTLA-4 antibodies and uses thereof
MX2019005947A (es) 2016-11-28 2019-08-26 Chugai Pharmaceutical Co Ltd Molecula de union a ligando que tiene actividad de union a ligando ajustable.
AU2017364817B2 (en) 2016-11-28 2023-11-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
WO2018110555A1 (ja) 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
US11813307B2 (en) 2017-06-02 2023-11-14 Merck Patent Gmbh Polypeptides binding ADAMTS5, MMP13 and aggrecan
US11603401B2 (en) 2017-06-02 2023-03-14 Ablynx N.V. Aggrecan binding immunoglobulins
AU2018298060B2 (en) 2017-07-03 2021-02-25 Torque Therapeutics, Inc. Immunostimulatory fusion molecules and uses thereof
US20190038935A1 (en) 2017-08-07 2019-02-07 Timofey Ignatyev Exercise game and apparatus employing color-changing base locations
CN107602706B (zh) 2017-10-16 2020-12-04 湖北大学 一种切割效率增强的hrv 3c蛋白酶底物突变体及其应用
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
KR102020131B1 (ko) 2017-12-29 2019-09-09 박성원 광경화성 조성물 및 이를 이용하여 제조된 성형품
US20210260163A1 (en) 2018-03-09 2021-08-26 AskGene Pharma, Inc. Novel cytokine prodrugs
IL278615B1 (en) 2018-05-14 2025-10-01 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of using them
ES2955511T3 (es) 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Polipéptidos de interleucina 2 activables y métodos de uso de los mismos
US20210253672A1 (en) 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
WO2019230867A1 (en) 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
US20210155701A1 (en) 2018-05-30 2021-05-27 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
US20210355219A1 (en) 2018-09-21 2021-11-18 Harpoon Therapeutics, Inc. Conditionally activated target-binding molecules
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
JP7716979B2 (ja) 2019-06-05 2025-08-01 中外製薬株式会社 プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド
US20220281936A1 (en) 2019-07-25 2022-09-08 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
JP2023510994A (ja) 2020-01-20 2023-03-16 中外製薬株式会社 リガンド結合融合タンパク質
TW202321281A (zh) 2021-07-19 2023-06-01 日商中外製藥股份有限公司 使用融合多肽之蛋白酶媒介之靶特異性細胞激素傳遞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Puskas J., et al., "Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases",Immunology,Vol. 123, 無2011, page 206–220. *

Also Published As

Publication number Publication date
US20200207846A1 (en) 2020-07-02
IL266827A (en) 2019-08-29
IL266827B2 (en) 2025-04-01
AU2017364818B2 (en) 2024-11-21
TW201833136A (zh) 2018-09-16
CA3039316A1 (en) 2018-05-31
JPWO2018097308A1 (ja) 2019-10-17
CN110214151A (zh) 2019-09-06
US20250034756A1 (en) 2025-01-30
TW202235438A (zh) 2022-09-16
US12060654B2 (en) 2024-08-13
JP7626577B2 (ja) 2025-02-07
JP2023075256A (ja) 2023-05-30
MX2024003516A (es) 2024-04-01
EP3546480A1 (en) 2019-10-02
AU2017364818C1 (en) 2025-05-15
AU2017364818A1 (en) 2019-05-23
WO2018097308A1 (ja) 2018-05-31
BR112019008265A2 (pt) 2019-07-09
KR102533814B1 (ko) 2023-05-19
MX2024003513A (es) 2024-04-08
KR20190087525A (ko) 2019-07-24
RU2019117223A (ru) 2020-12-28
KR20230073346A (ko) 2023-05-25
EP3546480A4 (en) 2020-07-29
MX2019005947A (es) 2019-08-26
JP2025041812A (ja) 2025-03-26
JP7671794B2 (ja) 2025-05-02
RU2019117223A3 (enExample) 2021-02-18
IL266827B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
JP7671794B2 (ja) リガンド結合活性が調整可能なリガンド結合分子
JP7751606B2 (ja) リガンド結合活性が調整可能なリガンド結合分子
US20230069996A1 (en) Ligand-binding fusion proteins
JP2024056935A (ja) 単ドメイン抗体含有リガンド結合分子
RU2803067C2 (ru) Лигандсвязывающая молекула с регулируемой лигандсвязывающей активностью
RU2852787C2 (ru) Лигандсвязывающая молекула, обладающая регулируемой лигандсвязывающей активностью
HK40007165A (en) Ligand-binding molecule having adjustable ligand binding activity
HK40029817A (en) Ligand-binding molecule having adjustable ligand-binding activity

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent